Search

Your search keyword '"Shvidel, Lev"' showing total 12 results
Start Over Author "Shvidel, Lev" Publication Year Range Last 3 years
12 results on '"Shvidel, Lev"'

2. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study

Author

Levi, Shai, Bronstein, Yotam, Goldschmidt, Neta, Morabito, Fortunato, Ziv-Baran, Tomer, Del Poeta, Giovanni, Bairey, Osnat, Del Principe, Maria Ilaria, Fineman, Riva, Mauro, Francesca Romana, Gutwein, Odit, Reda, Gianluigi, Ruchlemer, Rosa, Sportoletti, Paolo, Laurenti, Luca, Shvidel, Lev, Coscia, Marta, Tadmor, Tamar, Varettoni, Marzia, Aviv, Ariel, Murru, Roberta, Braester, Andrei, Chiarenza, Annalisa, Visentin, Andrea, Pietrasanta, Daniela, Loseto, Giacomo, Zucchetto, Antonella, Bomben, Riccardo, Olivieri, Jacopo, Neri, Antonio, Rossi, Davide, Gaidano, Gianluca, Trentin, Livio, Foà, Robin, Cuneo, Antonio, Perry, Chava, Gattei, Valter, Gentile, Massimo, and Herishanu, Yair

Subjects
Settore MED/15
Published
2023

5. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “ Real‐World ” study

Author

Levi, Shai, primary, Bronstein, Yotam, additional, Goldschmidt, Neta, additional, Morabito, Fortunato, additional, Ziv‐Baran, Tomer, additional, Del Poeta, Giovanni, additional, Bairey, Osnat, additional, Del Principe, Maria Ilaria, additional, Fineman, Riva, additional, Mauro, Francesca Romana, additional, Gutwein, Odit, additional, Reda, Gianluigi, additional, Ruchlemer, Rosa, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Shvidel, Lev, additional, Coscia, Marta, additional, Tadmor, Tamar, additional, Varettoni, Marzia, additional, Aviv, Ariel, additional, Murru, Roberta, additional, Braester, Andrei, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Olivieri, Jacopo, additional, Neri, Antonio, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Trentin, Livio, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Perry, Chava, additional, Gattei, Valter, additional, Gentile, Massimo, additional, and Herishanu, Yair, additional

Published
2022
Full Text
View/download PDF

8. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real‐World" study.

Author

Levi, Shai, Bronstein, Yotam, Goldschmidt, Neta, Morabito, Fortunato, Ziv‐Baran, Tomer, Del Poeta, Giovanni, Bairey, Osnat, Del Principe, Maria Ilaria, Fineman, Riva, Mauro, Francesca Romana, Gutwein, Odit, Reda, Gianluigi, Ruchlemer, Rosa, Sportoletti, Paolo, Laurenti, Luca, Shvidel, Lev, Coscia, Marta, Tadmor, Tamar, Varettoni, Marzia, and Aviv, Ariel

Published
2023
Full Text
View/download PDF

9. Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study

Author

Herishanu, Yair, primary, Goldschmidt, Neta, additional, Itchaki, Gilad, additional, Levi, Itai, additional, Aviv, Ariel, additional, Fineman, Riva, additional, Dally, Najib, additional, Tadmor, Tamar, additional, Ruchlemer, Rosa, additional, Abadi, Uri, additional, Shvidel, Lev, additional, Braester, Andrei, additional, Cohen, Raanan, additional, Frankel, Neta, additional, Ofek, Keren, additional, Berelovich, Jenia, additional, Grunspan, Moshe, additional, and Benjamini, Ohad, additional

Published
2021
Full Text
View/download PDF

10. Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Author

Herishanu, Yair, primary, Levi, Shai, additional, Goldschmidt, Neta, additional, Morabito, Fortunato, additional, Bairey, Osnat, additional, Del Poeta, Giovanni, additional, Ziv Baran, Tomer, additional, Fineman, Riva, additional, Mauro, Francesca Romana, additional, Gutwein, Odit, additional, Reda, Gianluigi, additional, Ruchlemer, Rosa, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Shvidel, Lev, additional, Coscia, Marta, additional, Tadmor, Tamar, additional, Varettoni, Marzia, additional, Aviv, Ariel, additional, Murru, Roberta, additional, Breaster, Andrei, additional, Bronstein, Yotam, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Olivieri, Jacopo, additional, Neri, Antonino, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Trentin, Livio, additional, Foa, Robin, additional, Cuneo, Antonio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

11. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome.

Author

Levy, Ilana, Lavi, Avital, Zimran, Eran, Grisariu, Sigal, Aumann, Shlomzion, Itchaki, Gilad, Berger, Tamar, Raanani, Pia, Harel, Reut, Aviv, Ariel, Lavi, Noa, Zuckerman, Tsila, Shvidel, Lev, Jarchowsky, Osnat, Ellis, Martin, Herzog Tzarfati, Katrin, Koren-Michowitz, Maya, Sherf, Yehonatan, Levi, Itai, and Sofer, Orit

Subjects
COVID-19, HEMATOLOGIC malignancies, CONVALESCENT plasma, TREATMENT effectiveness, RETROSPECTIVE studies
Abstract

This national Israeli multicenter retrospective study aimed to characterize the clinical course of COVID-19 infection among patients with hematological malignancies, with special emphasis on treatment efficacy and outcome. Clinical and laboratory data from haemato-oncological patients diagnosed with COVID-19 from 16 medical centers were centrally reported. Multivariate regression analyses were used to determine variables associated with severe disease, hospitalization, and mortality. In total, 313 patients were included: 103 (35.7%) developed severe/critical respiratory infection, 178 (61.4%) were hospitalized, and 60 (20.0%) died. Age > 70 years was associated with severe/critical disease (p = 0.036) and mortality (p = 0.023), hypertension with severe/critical disease (p = 0.046) and hospitalization (p = 0.001), active haemato-oncological treatment with hospitalization (p = 0.009), and remdesivir treatment was associated with decreased mortality (p = 0.021). Convalescent plasma, enoxaparin, and corticosteroids resulted in no clinical benefit. In conclusion, COVID-19 infection seems particularly severe in patients with hematological malignancies, and of all examined therapies, remdesivir appears to be the most effective. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

12. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.

Author

Benjamini O, Rokach L, Itchaki G, Braester A, Shvidel L, Goldschmidt N, Shapira S, Dally N, Avigdor A, Rahav G, Lustig Y, Ben David SS, Fineman R, Paz A, Bairey O, Polliack A, Levy I, and Tadmor T

Subjects
Antibodies, Viral, BNT162 Vaccine, COVID-19 Vaccines adverse effects, Humans, RNA, Messenger genetics, SARS-CoV-2, COVID-19 prevention & control, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Abstract

Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95% in immunocompetent individuals, was introduced. We investigated the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with CLL from nine medical centers in Israel, Overall 400 patients were included, of whom 373 were found to be eligible for the analysis of antibody response. The vaccine appeared to be safe and only grade 1-2 adverse events were seen in 50% of the patients. Following the second dose, an antibody response was detected in 43% of the cohort. Among these CLL patients, 61% of the treatment-na ve patients responded to the vaccine, while responses developed in only 18% of those with ongoing disease, 37% of those previously treated with a BTK inhibitor and 5% of those recently given an anti-CD20 antibody. Among patients treated with BCL2 as monotherapy or in combination with anti-CD20, 62% and 14%, respectively, developed an immune response. There was a high concordance between neutralizing antibodies and positive serological response to spike protein. Based on our findings we developed a simple seven-factor score including timing of any treatment with anti-CD20, age, treatment status, and IgG, IgA, IgM and hemoglobin levels. The sum of all the above parameters can serve as a possible estimate to predict whether a given CLL patient will develop sufficient antibodies. In conclusion, the BNT162b2 mRNA COVID-19 vaccine was found to be safe in patients with CLL, but its efficacy is limited, particularly in treated patients.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results